查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1961110

人體類器官市場－全球產業規模、佔有率、趨勢、機會與預測：按來源、器官類型、地區和競爭格局分類，2021-2031年

Human Organoids Market - Global Industry Size, Share, Trends, Opportunities and Forecast, Segmented By Source, By Organ Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球人類類器官市場預計將從 2025 年的 5.1224 億美元成長到 2031 年的 6.5528 億美元，複合年成長率為 4.19%。

這個產業的核心在於開發和商業化利用幹細胞建構的3D體外組織模型，以模擬人體器官的結構和功能特徵。推動這一成長的關鍵因素包括：迫切需要生理上精確的臨床前模型來降低藥物研發的高失敗率；以及日益成長的倫理和監管壓力，要求盡可能減少藥物研究中對動物試驗的依賴。與生物生物銀行數位化等短期趨勢不同，這些促進因素旨在解決藥物發現和個人化醫療中存在的根本性運作效率低下問題。

市場概覽
預測期 2027-2031
市場規模：2025年 5.1224億美元
市場規模：2031年 6.5528億美元
複合年成長率：2026-2031年 4.19%
成長最快的細分市場 成體幹細胞
最大的市場 北美洲

儘管存在這些成長要素，但缺乏標準化通訊協定和監管檢驗不足目前阻礙了行業層面的推廣應用，並為許多機構設置了重大准入門檻。這種對採用替代檢測方法的猶豫態度也反映在近期的產業數據中。根據皮斯托亞聯盟（Pistoia Alliance）的調查，2024年接受調查的生命科學專業人士中，77%的人表示尚未將類器官等非動物模型整合到其研發流程中，主要原因是擔心監管合規性和數據可重複性問題。

市場促進因素

隨著監管機構和製藥公司致力於降低傳統體內模型的高失敗率，動物試驗替代方案的出現正在從根本上改變市場結構。這項轉變深受法規結構（例如FDA現代化法案2.0）的影響，該法案鼓勵使用非動物替代方案來產生更具預測性的人體毒性數據。因此，安全藥理學領域中動物試驗的替代工具正在迅速商業化。例如，ATCC於2024年2月宣布的「ATCC-Tissue Dynamics夥伴關係」揭示了雙方將共同開發一種與人體相關的類心臟器官試劑盒，旨在透過提供比動物模型更高的生理相關性來改善心臟安全性測試並降低藥物研發風險。

再生醫學領域研究經費和投資的激增進一步推動了市場擴張，為克服規模化和標準化障礙提供了必要的資金。領先的製藥公司正積極透過高價值的合作研究，檢驗類器官技術在傳統動物模型難以勝任的疾病領域的有效性。勃林格殷格翰與Ochre Bio的策略合作就是一個典型的例子。根據2024年4月發布的「勃林格殷格翰與Ochre Bio合作」新聞稿，該公司承諾投入高達10億美元，利用先進的人類肝臟模型，探索治療慢性肝病的新治療方法。此外，為確保商業性可行性，工業化生產的資金也不斷增加。例如，2024年4月Vertex與TreeFrog Therapeutics授權合約”，該協議價值高達7.8億美元，旨在利用專有的C-Stem技術擴大細胞療法的生產規模。

市場挑戰

缺乏標準化通訊協定和監管檢驗不足，嚴重阻礙了全球人類類器官市場的產業化規模化發展。由於調查方法不一致導致數據輸出存在差異，製藥公司和研究機構仍猶豫是否將這些模型全面整合到關鍵決策流程中。當實驗室工作流程在培養條件和表徵指標方面存在顯著差異時，最終數據缺乏監管申報所需的穩健性。因此，監管機構難以製定基於類器官的安全性和有效性評估的通用指南，迫使企業必須維持高成本的雙重測試系統，其中包括傳統的動物模型。

這種缺乏統一性直接阻礙了市場擴張，使類器官主要局限於探索性研究，而無法應用於檢驗的監管應用。近期產業調查結果凸顯了這種操作上的碎片化程度。根據國際藥物研發創新與品質聯盟（IQ Consortium）2025年的調查，儘管76%的成員公司都在使用類器官等人源化肝臟模型，但該行業仍然面臨「方法上的異質性」和不一致的風險評估策略。這種持續存在的差異削弱了這些模型作為體內試驗唯一替代方案所需的可信度，從而阻礙了其更廣泛的商業性應用。

市場趨勢

將人工智慧 (AI) 和自動化技術融入培養流程，正迅速解決類器官培養的關鍵瓶頸問題，例如可重複性和勞動密集流程。為了管理成熟組織模型所需的複雜餵食和監測方案，實驗室擴大採用機器學習驅動的機器人系統，從而最大限度地減少人為錯誤和變異性。近期的一些技術標竿也印證了這種操作方式的轉變。根據 Molecular Devices 公司 2025 年 8 月發布的新聞稿，引入自動化振盪培養技術後，腦類器官培養板每週的人工操作量減少了高達 90%，實際工作時間從 27 小時縮短至僅幾個小時。

同時，受託研究機構(CRO) 拓展高通量類器官篩檢服務，正推動病患來源模型在大規模臨床前試驗的應用產業化。 CRO 透過整合大量特徵明確的腫瘤樣細胞庫，為製藥客戶提供“體外臨床試驗”，從而在人體試驗前快速篩選出有效患者。這種商業性能力的提昇在服務組合的成長中得到了清楚的體現。例如，根據 Crown Bioscience 2025 年 5 月發表的報導《利用類器官重新定義精準醫療》，該公司已建立了一個大型商業生物樣本庫，其中包含約 1000 個涵蓋 22 種組織類型的類器官模型，以支持大規模藥物和模型試驗。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球人類類器官市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 供應來源（成體幹細胞、誘導性多功能幹細胞、胚胎幹細胞、其他）
    • 依器官類型（胃模型、腸模型、肝臟模型、胰臟模型、肺部模型、腦部模型、腎臟模型、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美人類類器官市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲人類類器官市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區人類類器官市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東與非洲人類類器官市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲人類類器官市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球人類類器官市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • American Type Culture Collection（ATCC）
  • Thermo Fisher Scientific Inc.
  • STEMCELL Technologies Canada Inc.
  • Merck KGaA
  • Corning Incorporated
  • Bio-Techne Corporation
  • ACROBIOSYSTEMS INC.
  • AMS Biotechnology（Europe）Ltd
  • Qkine Ltd.
  • PRIMACYT Cell Culture Technology GmbH

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 28070

The Global Human Organoids Market is projected to expand from a valuation of USD 512.24 Million in 2025 to USD 655.28 Million by 2031, reflecting a CAGR of 4.19%. This industry centers on the creation and commercialization of three-dimensional in vitro tissue models engineered from stem cells to mimic the structural and functional properties of human organs. The primary drivers of this growth include the urgent need for physiologically accurate preclinical models to lower high drug failure rates, alongside intensifying ethical and regulatory pressure to minimize reliance on animal testing in pharmaceutical research. Unlike temporary trends such as the digitization of bio-banking, these drivers address fundamental operational inefficiencies within drug discovery and personalized medicine.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 512.24 Million
Market Size 2031USD 655.28 Million
CAGR 2026-20314.19%
Fastest Growing SegmentAdult Stem Cells
Largest MarketNorth America

Despite these growth factors, widespread industrial adoption is currently hindered by the lack of standardized protocols and regulatory validation, creating significant barriers to entry for many organizations. This hesitation to adopt alternative testing methods is reflected in recent industry data. According to the Pistoia Alliance, in 2024, 77% of surveyed life sciences professionals indicated they were not yet integrating non-animal models, such as organoids, into their research and development workflows, largely citing concerns regarding regulatory compliance and data reproducibility.

Market Driver

The shift toward alternatives to animal testing is fundamentally reshaping the market as regulatory bodies and pharmaceutical companies strive to reduce the high attrition rates associated with traditional in vivo models. This transition is heavily influenced by the implementation of regulatory frameworks like the FDA Modernization Act 2.0, which promotes the use of non-animal alternatives for generating more predictive human toxicity data. Consequently, the industry is seeing rapid commercialization of tools designed to replace animal testing in safety pharmacology. For example, according to ATCC in February 2024, the 'ATCC and Tissue Dynamics Partnership' was announced to collaboratively develop human-relevant cardiac organoid kits aimed at improving cardiac safety testing and mitigating drug development risks by offering higher physiological relevance than animal models.

Market expansion is further supported by a surge in research funding and investments in regenerative medicine, providing the capital necessary to overcome scalability and standardization hurdles. Major pharmaceutical companies are actively validating organoid technology through high-value collaborations in disease areas where animal models have historically failed. A key example is the strategic deal between Boehringer Ingelheim and Ochre Bio; as per the April 2024 'Boehringer Ingelheim and Ochre Bio Partnership' press release, the company committed up to $1 billion in potential payments to discover novel treatments for chronic liver diseases using advanced human liver models. Additionally, capital is increasingly targeting industrial manufacturing to ensure commercial viability, as highlighted by the April 2024 'Vertex and TreeFrog Therapeutics License Agreement,' where a collaboration valued at up to $780 million was established to scale cell therapy manufacturing using proprietary C-Stem technology.

Market Challenge

The absence of standardized protocols and regulatory validation represents a significant barrier to the industrial scalability of the Global Human Organoids Market. Pharmaceutical companies and research organizations remain hesitant to fully integrate these models into critical decision-making processes because inconsistent methodologies result in variable data outputs. When laboratory workflows differ substantially in culture conditions and characterization metrics, the resulting data lacks the robustness required for regulatory submissions. Consequently, regulatory bodies struggle to establish universal guidelines for organoid-based safety and efficacy assessments, compelling companies to maintain expensive dual testing streams that include traditional animal models.

This lack of uniformity directly restricts market expansion by limiting organoids primarily to exploratory research rather than validated regulatory applications. The extent of this operational fragmentation is underscored by recent industry findings. According to a 2025 survey by the International Consortium for Innovation and Quality in Pharmaceutical Development (IQ Consortium), although 76% of member companies utilized humanized liver models such as organoids, the industry continues to grapple with "heterogeneity in approaches" and a lack of consistent risk assessment strategies. This persistent variability undermines the confidence required for these models to function as standalone replacements for in vivo testing, thereby stalling their broader commercial adoption.

Market Trends

The integration of artificial intelligence and automation into culture processes is rapidly addressing the critical bottlenecks of reproducibility and labor intensity in organoid maintenance. Laboratories are increasingly utilizing machine learning-driven robotic systems to manage the complex feeding and monitoring schedules necessary for mature tissue models, thereby minimizing human error and variability. This operational shift is demonstrated by recent technological benchmarks; according to a Molecular Devices press release in August 2025, the integration of automated rocking incubation reduced the weekly manual labor for maintaining brain organoid plates by up to 90%, cutting hands-on time from 27 hours to just a few hours.

Simultaneously, the expansion of high-throughput organoid screening services by Contract Research Organizations (CROs) is industrializing the use of patient-derived models for large-scale preclinical trials. CROs are aggregating extensive libraries of well-characterized tumoroids to offer pharmaceutical clients "clinical trials in a dish," enabling the rapid stratification of patient responders prior to human testing. This scaling of commercial capabilities is evident in the growth of service portfolios; for instance, according to Crown Bioscience's May 2025 article 'Redefining Precision Medicine with Organoids,' the company has established a massive commercial biobank containing nearly 1,000 organoid models across 22 different tissue types to support large-scale drug and model testing.

Key Market Players

  • American Type Culture Collection (ATCC)
  • Thermo Fisher Scientific Inc.
  • STEMCELL Technologies Canada Inc.
  • Merck KGaA
  • Corning Incorporated
  • Bio-Techne Corporation
  • ACROBIOSYSTEMS INC.
  • AMS Biotechnology (Europe) Ltd
  • Qkine Ltd.
  • PRIMACYT Cell Culture Technology GmbH

Report Scope

In this report, the Global Human Organoids Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Human Organoids Market, By Source

  • Adult Stem Cells
  • Induced Pluripotent Stem Cells
  • Embryonic Stem Cells
  • Others

Human Organoids Market, By Organ Type

  • Stomach Models
  • Intestine Models
  • Liver Models
  • Pancreatic Models
  • Lung Models
  • Brain Models
  • Kidney Models
  • Others

Human Organoids Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Human Organoids Market.

Available Customizations:

Global Human Organoids Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Human Organoids Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Source (Adult Stem Cells, Induced Pluripotent Stem Cells, Embryonic Stem Cells, Others)
    • 5.2.2. By Organ Type (Stomach Models, Intestine Models, Liver Models, Pancreatic Models, Lung Models, Brain Models, Kidney Models, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Human Organoids Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Source
    • 6.2.2. By Organ Type
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Human Organoids Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Source
        • 6.3.1.2.2. By Organ Type
    • 6.3.2. Canada Human Organoids Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Source
        • 6.3.2.2.2. By Organ Type
    • 6.3.3. Mexico Human Organoids Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Source
        • 6.3.3.2.2. By Organ Type

7. Europe Human Organoids Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Source
    • 7.2.2. By Organ Type
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Human Organoids Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Source
        • 7.3.1.2.2. By Organ Type
    • 7.3.2. France Human Organoids Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Source
        • 7.3.2.2.2. By Organ Type
    • 7.3.3. United Kingdom Human Organoids Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Source
        • 7.3.3.2.2. By Organ Type
    • 7.3.4. Italy Human Organoids Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Source
        • 7.3.4.2.2. By Organ Type
    • 7.3.5. Spain Human Organoids Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Source
        • 7.3.5.2.2. By Organ Type

8. Asia Pacific Human Organoids Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Source
    • 8.2.2. By Organ Type
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Human Organoids Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Source
        • 8.3.1.2.2. By Organ Type
    • 8.3.2. India Human Organoids Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Source
        • 8.3.2.2.2. By Organ Type
    • 8.3.3. Japan Human Organoids Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Source
        • 8.3.3.2.2. By Organ Type
    • 8.3.4. South Korea Human Organoids Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Source
        • 8.3.4.2.2. By Organ Type
    • 8.3.5. Australia Human Organoids Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Source
        • 8.3.5.2.2. By Organ Type

9. Middle East & Africa Human Organoids Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Source
    • 9.2.2. By Organ Type
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Human Organoids Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Source
        • 9.3.1.2.2. By Organ Type
    • 9.3.2. UAE Human Organoids Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Source
        • 9.3.2.2.2. By Organ Type
    • 9.3.3. South Africa Human Organoids Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Source
        • 9.3.3.2.2. By Organ Type

10. South America Human Organoids Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Source
    • 10.2.2. By Organ Type
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Human Organoids Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Source
        • 10.3.1.2.2. By Organ Type
    • 10.3.2. Colombia Human Organoids Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Source
        • 10.3.2.2.2. By Organ Type
    • 10.3.3. Argentina Human Organoids Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Source
        • 10.3.3.2.2. By Organ Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Human Organoids Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. American Type Culture Collection (ATCC)
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Thermo Fisher Scientific Inc.
  • 15.3. STEMCELL Technologies Canada Inc.
  • 15.4. Merck KGaA
  • 15.5. Corning Incorporated
  • 15.6. Bio-Techne Corporation
  • 15.7. ACROBIOSYSTEMS INC.
  • 15.8. AMS Biotechnology (Europe) Ltd
  • 15.9. Qkine Ltd.
  • 15.10. PRIMACYT Cell Culture Technology GmbH

16. Strategic Recommendations

17. About Us & Disclaimer